Market Overview

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

Share:
Related PFE
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Morgan Stanley's Major Pharma Q1 Preview
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog (Zacks)

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Pfizer closed on Thursday at $28.44.

Latest Ratings for PFE

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015Deutsche BankMaintainsBuy
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...